Physician
Tricity Pain Associates PA
Tricity Pain Associates PA was paid $485K by Medicaid between May 2021 and Dec 2024, across 27 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 75% of everything it billed.
33Billing provider infoTRICITY PAIN ASSOCIATES PA
SAN ANTONIO, TX 78258
SAN ANTONIO, TX 78258
33aNPI1619244720assigned 11/18/2011
33bProvider typeAnesthesiology Physician
28Total paid$485K
24GClaims15,028
24DCodes billed27
24AFirst – last monthMay 2021 – Dec 2024
Compared with peers
Next to other Anesthesiology Physician providers in Texas
Rank by total paid#33 of 134
Median peer was paid$34K
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 615 | $11K | |
| 2022 | 4,658 | $121K | |
| 2023 | 7,691 | $235K | |
| 2024incomplete | 2,064 | $117K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 75% | 7,985 | 7,343 | $364K |
| 64483 | 10% | 384 | 318 | $50K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.4% | 1,128 | 1,067 | $36K |
| 80305 | 1.9% | 2,175 | 2,043 | $9K | |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 1.3% | 142 | 137 | $6K |
| 20553 | 1.2% | 504 | 452 | $6K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 499 | 484 | $4K |
| 62321 | <1% | 20 | 12 | $1K | |
| 64493 | <1% | 16 | 12 | $1K | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 23 | 23 | $1K |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 548 | 494 | $1K |
| 76942 | <1% | 116 | 111 | $938.45 |
15 more codes
| 80336 | <1% | 56 | $930.80 | |
| 80332 | <1% | 56 | $908.44 | |
| 80338 | <1% | 56 | $585.00 | |
| 64494 | <1% | 16 | $541.30 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 86 | $475.99 |
| 80355 | <1% | 59 | $445.50 | |
| 80366 | <1% | 57 | $385.84 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 506 | $344.55 |
| 99442 | <1% | 28 | $321.40 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 426 | $260.31 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 34 | $90.96 |
| 99072 | 0% | 21 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 14 | $0.00 |
| 99441 | 0% | 21 | $0.00 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 0% | 52 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialEFIRD, KENNETH (COO)